![Transparency Market Researchが調査・発行した産業分析レポートです。世界のウイルス性呼吸器感染症治療薬市場2020年ｰ2030年：薬剤種類別（抗生物質、非ステロイド性抗炎症薬[NSAIDS]、咳止め薬、鼻充血除去薬、その他）、感染タイプ別、投与経路別、購入方法別、流通チャネル別 / Respiratory Virus Infection Drugs Market (Drug Type: Antibiotics, Non-Steroidal Anti-Inflammatory Drugs [NSAIDS], Cough Suppressants, Nasal Decongestants, and Others; Infection Type: Respiratory Syncytial Virus [RSV] Infection, Influenza Virus Infection, Parainfluenza Virus Infection, Adenovirus Infection, Rhinovirus Infection, and Others; Route of Administration: Oral and Parenteral; Mode of Purchase: Prescription-based Drugs and Over-the-counter Drugs; and Distribution Channel: Hospital Pharmacies, Drug Stores, Retail Pharmacies, Clinics, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 - 2030 / MRC2103G036資料のイメージです。](https://www.marketresearch.co.jp/images-folder2/report-contents-12.gif) | • レポートコード：MRC2103G036 • 出版社/出版日：Transparency Market Research / 2021年1月4日 • レポート形態：英文、PDF、238ページ • 納品方法：Eメール • 産業分類：医薬品 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Site Licence | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Enterprisewide Licence | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の本調査資料では、世界のウイルス性呼吸器感染症治療薬市場を広く調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、キーインサイト、薬剤種類別（抗生物質、非ステロイド性抗炎症薬（NSAIDS）、咳抑制剤、鼻充血除去薬、その他）分析、感染タイプ別分析、投与経路別分析、購入方法別分析、流通チャネル別分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況など、以下の構成でまとめております。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・キーインサイト ・ウイルス性呼吸器感染症治療薬の世界市場規模：薬剤種類別（抗生物質、非ステロイド性抗炎症薬（NSAIDS）、咳抑制剤、鼻充血除去薬、その他） ・ウイルス性呼吸器感染症治療薬の世界市場規模：感染タイプ別 ・ウイルス性呼吸器感染症治療薬の世界市場規模：投与経路別 ・ウイルス性呼吸器感染症治療薬の世界市場規模：購入方法別 ・ウイルス性呼吸器感染症治療薬の世界市場規模：流通チャネル別 ・ウイルス性呼吸器感染症治療薬の世界市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ） ・競争状況 |
Respiratory Virus Infection Drugs Market – Scope of the Report
TMR’s report on the global respiratory virus infection drugs market studies past as well as current growth trends and opportunities to gain valuable insights of these indicators of the market during the forecast period from 2020 to 2030. The report provides revenue of the global respiratory virus infection drugs market for the period 2018–2030, considering 2019 as the base year and 2030 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global respiratory virus infection drugs market during the forecast period.
The report has been prepared after primary and secondary researches. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global respiratory virus infection drugs market.
Secondary research also included Internet sources, statistical data from government agencies, websites, company presentations, sales data, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various phenomenon in the global respiratory virus infection drugs market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global respiratory virus infection drugs market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global respiratory virus infection drugs market.
The report delves into the competition landscape of the global respiratory virus infection drugs market. Key players operating in the global respiratory virus infection drugs market have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the global respiratory virus infection drugs market that have been profiled in this report.
Key Questions Answered in Respiratory Virus Infection Drugs Market Report
What is the scope of growth for product companies in the global respiratory virus infection drugs market?
What will be the Y-o-Y growth of the global respiratory virus infection drugs market between 2020 and 2030?
What is the influence of changing trends in technologies on the global respiratory virus infection drugs market?
Will North America continue to be the most profitable market for respiratory virus infection drugs?
Which factors are anticipated to hamper the global respiratory virus infection drugs market during the forecast period?
Which are the leading companies in the global respiratory virus infection drugs market?
Research Methodology
A unique methodology has been utilized by TMR to conduct comprehensive research on the growth of the global respiratory virus infection drugs market and arrive at conclusions on its growth prospects. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.
Secondary research sources referred to by analysts during the production of the global respiratory virus infection drugs market report include statistics from company annual reports, SEC filings, company websites, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of TMR’s study on the respiratory virus infection drugs market as primary methods.
These primary research respondents have provided exclusive information during interviews, which serves as a validation from the respiratory virus infection drugs market leaders. Access to an extensive internal repository and external proprietary databases enabled this report to address specific details and questions about the global respiratory virus infection drugs market with accuracy. The study also uses the top-down approach to assess the revenues of each segment and the bottom-up approach to counter-validate them. This has helped in reaching TMR’s estimates on future prospects of the global respiratory virus infection drugs more reliably and accurately.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Respiratory Virus Infection Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Drug Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Respiratory Virus Infection Drugs Market Analysis and Forecast, 2018–2030
5. Key Insights
5.1. Healthcare Industry Overview
5.2. Pipeline Analysis (asthma and COPD)
5.3. Regulatory Scenario
5.4. Disease Prevalence Rate in Key Countries
5.5. Key Market Events
5.6. COVID-19 Pandemic Impact on Industry
6. Global Respiratory Virus Infection Drugs Market Analysis and Forecast, by Drug Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Type, 2018–2030
6.3.1. Antibiotics
6.3.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
6.3.3. Cough Suppressants
6.3.4. Nasal Decongestants
6.3.5. Others
6.4. Market Attractiveness Analysis, by Drug Type
7. Global Respiratory Virus Infection Drugs Market Analysis and Forecast, by Infection Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Infection Type, 2018–2030
7.3.1. Respiratory Syncytial Virus (RSV) Infection
7.3.2. Influenza Virus Infection
7.3.3. Parainfluenza Virus Infection
7.3.4. Adenovirus Infection
7.3.5. Rhinovirus Infection
7.3.6. Others
7.4. Market Attractiveness Analysis, by Infection Type
8. Global Respiratory Virus Infection Drugs Market Analysis and Forecast, by Route of Administration
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Route of Administration, 2018–2030
8.3.1. Oral
8.3.2. Parenteral
8.4. Market Attractiveness Analysis, by Route of Administration
9. Global Respiratory Virus Infection Drugs Market Analysis and Forecast, by Mode of Purchase
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by Mode of Purchase, 2018–2030
9.3.1. Prescription-based Drugs
9.3.2. Over-the-Counter Drugs
9.4. Market Attractiveness Analysis, by Mode of Purchase
10. Global Respiratory Virus Infection Drugs Market Analysis and Forecast, by Distribution Channel
10.1. Introduction & Definition
10.2. Key Findings / Developments
10.3. Market Value Forecast, by Distribution Channel, 2018–2030
10.3.1. Hospital Pharmacies
10.3.2. Drug Stores
10.3.3. Retail Pharmacies
10.3.4. Clinics
10.3.5. Others
10.4. Market Attractiveness Analysis, by Distribution Channel
11. Global Respiratory Virus Infection Drugs Market Analysis and Forecast, by Region
11.1. Key Findings
11.2. Market Value Forecast, by Region
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Latin America
11.2.5. Middle East & Africa
11.3. Market Attractiveness Analysis, by Country/Region
12. North America Respiratory Virus Infection Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Type, 2018–2030
12.2.1. Antibiotics
12.2.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
12.2.3. Cough Suppressants
12.2.4. Nasal Decongestants
12.2.5. Others
12.3. Market Value Forecast, by Infection Type, 2018–2030
12.3.1. Respiratory syncytial viruses (RSV) Infection
12.3.2. Influenza Virus Infection
12.3.3. Parainfluenza Virus Infection
12.3.4. Adenovirus Infection
12.3.5. Rhinovirus Infection
12.3.6. Others
12.4. Market Value Forecast, by Route of Administration, 2018–2030
12.4.1. Oral
12.4.2. Parenteral
12.5. Market Value Forecast, by Mode of Purchase, 2018–2030
12.5.1. Prescription-based Drugs
12.5.2. Over-the-Counter Drugs
12.6. Market Value Forecast, by Distribution Channel, 2018–2030
12.6.1. Hospital Pharmacies
12.6.2. Drug Stores
12.6.3. Retail Pharmacies
12.6.4. Clinics
12.6.5. Others
12.7. Market Value Forecast, by Country, 2018–2030
12.7.1. U.S.
12.7.2. Canada
12.8. Market Attractiveness Analysis
12.8.1. By Drug Type
12.8.2. By Infection Type
12.8.3. By Route Of Administration
12.8.4. By Mode of Purchase
12.8.5. By Distribution Channel
12.8.6. By Country
13. Europe Respiratory Virus Infection Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Type, 2018–2030
13.2.1. Antibiotics
13.2.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
13.2.3. Cough Suppressants
13.2.4. Nasal Decongestants
13.2.5. Others
13.3. Market Value Forecast, by Infection Type, 2018–2030
13.3.1. Respiratory Syncytial Virus (RSV) Infection
13.3.2. Influenza Virus Infection
13.3.3. Parainfluenza Virus Infection
13.3.4. Adenovirus Infection
13.3.5. Rhinovirus Infection
13.3.6. Others
13.4. Market Value Forecast, by Route of Administration, 2018–2030
13.4.1. Oral
13.4.2. Parenteral
13.5. Market Value Forecast, by Mode of Purchase, 2018–2030
13.5.1. Prescription-based Drugs
13.5.2. Over-the-Counter Drugs
13.6. Market Value Forecast, by Distribution Channel, 2018–2030
13.6.1. Hospital Pharmacies
13.6.2. Drug Stores
13.6.3. Retail Pharmacies
13.6.4. Clinics
13.6.5. Others
13.7. Market Value Forecast, by Country/Sub-region, 2018–2030
13.7.1. Germany
13.7.2. U.K.
13.7.3. France
13.7.4. Spain
13.7.5. Italy
13.7.6. Rest of Europe
13.8. Market Attractiveness Analysis
13.8.1. By Drug Type
13.8.2. By Infection Type
13.8.3. By Route Of Administration
13.8.4. By Mode of Purchase
13.8.5. By Distribution Channel
13.8.6. By Country/Sub-region
14. Asia Pacific Respiratory Virus Infection Drugs Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Type, 2018–2030
14.2.1. Antibiotics
14.2.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
14.2.3. Cough Suppressants
14.2.4. Nasal Decongestants
14.2.5. Others
14.3. Market Value Forecast, by Infection Type, 2018–2030
14.3.1. Respiratory Syncytial Virus (RSV) Infection
14.3.2. Influenza Virus Infection
14.3.3. Parainfluenza Virus Infection
14.3.4. Adenovirus Infection
14.3.5. Rhinovirus Infection
14.3.6. Others
14.4. Market Value Forecast, by Route Of Administration, 2018–2030
14.4.1. Oral
14.4.2. Parenteral
14.5. Market Value Forecast, by Mode of Purchase, 2018–2030
14.5.1. Prescription-based Drugs
14.5.2. Over-the-Counter Drugs
14.6. Market Value Forecast, by Distribution Channel, 2018–2030
14.6.1. Hospital Pharmacies
14.6.2. Drug Stores
14.6.3. Retail Pharmacies
14.6.4. Clinics
14.6.5. Others
14.7. Market Value Forecast, by Country/Sub-region, 2018–2030
14.7.1. China
14.7.2. Japan
14.7.3. India
14.7.4. Australia & New Zealand
14.7.5. Rest of Asia Pacific
14.8. Market Attractiveness Analysis
14.8.1. By Drug Type
14.8.2. By Infection Type
14.8.3. By Route of Administration
14.8.4. By Mode of Purchase
14.8.5. By Distribution Channel
14.8.6. By Country/Sub-region
15. Latin America Respiratory Virus Infection Drugs Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Drug Type, 2018–2030
15.2.1. Antibiotics
15.2.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
15.2.3. Cough Suppressants
15.2.4. Nasal Decongestants
15.2.5. Others
15.3. Market Value Forecast, by Infection Type, 2018–2030
15.3.1. Respiratory Syncytial Virus (RSV) Infection
15.3.2. Influenza Virus Infection
15.3.3. Parainfluenza Virus Infection
15.3.4. Adenovirus Infection
15.3.5. Rhinovirus Infection
15.3.6. Others
15.4. Market Value Forecast, by Route of Administration, 2018–2030
15.4.1. Oral
15.4.2. Parenteral
15.5. Market Value Forecast, by Mode of Purchase, 2018–2030
15.5.1. Prescription-based Drugs
15.5.2. Over-the-Counter Drugs
15.6. Market Value Forecast, by Distribution Channel, 2018–2030
15.6.1. Hospital Pharmacies
15.6.2. Drug Stores
15.6.3. Retail Pharmacies
15.6.4. Clinics
15.6.5. Others
15.7. Market Value Forecast, by Country/Sub-region, 2018–2030
15.7.1. Brazil
15.7.2. Mexico
15.7.3. Rest of Latin America
15.8. Market Attractiveness Analysis
15.8.1. By Drug Type
15.8.2. By Infection Type
15.8.3. By Route of Administration
15.8.4. By Mode of Purchase
15.8.5. By Distribution Channel
15.8.6. By Country/Sub-region
16. Middle East & Africa Respiratory Virus Infection Drugs Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Drug Type, 2018–2030
16.2.1. Antibiotics
16.2.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
16.2.3. Cough Suppressants
16.2.4. Nasal Decongestants
16.2.5. Others
16.3. Market Value Forecast, by Infection Type, 2018–2030
16.3.1. Respiratory Syncytial Virus (RSV) Infection
16.3.2. Influenza Virus Infection
16.3.3. Parainfluenza Virus Infection
16.3.4. Adenovirus Infection
16.3.5. Rhinovirus Infection
16.3.6. Others
16.4. Market Value Forecast, by Route of Administration, 2018–2030
16.4.1. Oral
16.4.2. Parenteral
16.5. Market Value Forecast, by Mode of Purchase, 2018–2030
16.5.1. Prescription-based Drugs
16.5.2. Over-the-Counter Drugs
16.6. Market Value Forecast, by Distribution Channel, 2018–2030
16.6.1. Hospital Pharmacies
16.6.2. Drug Stores
16.6.3. Retail Pharmacies
16.6.4. Clinics
16.6.5. Others
16.7. Market Value Forecast, by Country/Sub-region, 2018–2030
16.7.1. GCC Countries
16.7.2. South Africa
16.7.3. Rest of Middle East & Africa
16.8. Market Attractiveness Analysis
16.8.1. By Drug Type
16.8.2. By Infection Type
16.8.3. By Route of Administration
16.8.4. By Mode of Purchase
16.8.5. By Distribution Channel
16.8.6. By Country/Sub-region
17. Competition Landscape
17.1. Market Player – Competition Matrix (by tier and size of companies)
17.2. Market Share Analysis/Ranking, by Company, 2019
17.3. Company Profiles
17.3.1. GlaxoSmithKline plc
17.3.1.1. Company Overview
17.3.1.2. Company Financials
17.3.1.3. Growth Strategies
17.3.1.4. SWOT Analysis
17.3.2. Merck & Co., Inc.
17.3.2.1. Company Overview
17.3.2.2. Company Financials
17.3.2.3. Growth Strategies
17.3.2.4. SWOT Analysis
17.3.3. AstraZeneca
17.3.3.1. Company Overview
17.3.3.2. Company Financials
17.3.3.3. Growth Strategies
17.3.3.4. SWOT Analysis
17.3.4. Boehringer Ingelheim International GmbH
17.3.4.1. Company Overview
17.3.4.2. Company Financials
17.3.4.3. Growth Strategies
17.3.4.4. SWOT Analysis
17.3.5. F. Hoffmann-La Roche Ltd.
17.3.5.1. Company Overview
17.3.5.2. Company Financials
17.3.5.3. Growth Strategies
17.3.5.4. SWOT Analysis
17.3.6. Teva Pharmaceutical Industries Ltd.
17.3.6.1. Company Overview
17.3.6.2. Company Financials
17.3.6.3. Growth Strategies
17.3.6.4. SWOT Analysis
17.3.7. Sanofi
17.3.7.1. Company Overview
17.3.7.2. Company Financials
17.3.7.3. Growth Strategies
17.3.7.4. SWOT Analysis
17.3.8. Cipla, Inc.
17.3.8.1. Company Overview
17.3.8.2. Company Financials
17.3.8.3. Growth Strategies
17.3.8.4. SWOT Analysis
17.3.9. CHIESI Farmaceutici S.p.A.
17.3.9.1. Company Overview
17.3.9.2. Company Financials
17.3.9.3. Growth Strategies
17.3.9.4. SWOT Analysis
17.3.10. Orion Corporation
17.3.10.1. Company Overview
17.3.10.2. Growth Strategies
17.3.10.3. SWOT Analysis
Table 01: Global Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2018–2030
Table 02: Global Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Infection Type, 2018–2030
Table 03: Global Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 04: Global Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2018–2030
Table 05: Global Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 06: Global Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Region, 2018–2030
Table 07: North America Respiratory Virus Infection Drugs Market Revenue (US$ Mn) Forecast, by Country, 2018–2030
Table 08: North America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2018–2030
Table 09: North America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Infection Type, 2018–2030
Table 10: North America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 11: North America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Mode of Purchase, 2018–2030
Table 12: North America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 13: Europe Respiratory Virus Infection Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 14: Europe Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2018–2030
Table 15: Europe Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Infection Type, 2018–2030
Table 16: Europe Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 17: Europe Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Mode of Purchase, 2018–2030
Table 18: Europe Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 19: Asia Pacific Respiratory Virus Infection Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 20: Asia Pacific Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2018–2030
Table 21: Asia Pacific Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Infection Type, 2018–2030
Table 22: Asia Pacific Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 23: Asia Pacific Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Mode of Purchase, 2018–2030
Table 24: Asia Pacific Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 25: Latin America Respiratory Virus Infection Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 26: Latin America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2018–2030
Table 27: Latin America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Infection Type, 2018–2030
Table 28: Latin America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 29: Latin America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Mode of Purchase, 2018–2030
Table 30: Latin America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 31: Middle East & Africa Respiratory Virus Infection Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 32: Middle East & Africa Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2018–2030
Table 33: Middle East & Africa Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Infection Type, 2018–2030
Table 34: Middle East & Africa Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 35: Middle East & Africa Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Mode of Purchase, 2018–2030
Table 36: Middle East & Africa Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030